GÉTICA 2021

33 [ F I T C á n c e r - 7 ] Table I. List of case reports of hemophagocytic lymphohistiocytosis in oncological patients with immune checkpoint inhibitors Immunotherapy Primary tumor Bone marrow biopsy Neurological symptoms Treatment Clinical outcomes Takeshita et al., 2017 Nivolumab NSCLC + No Steroids Improvement Malissen et al., 2017 Nivolumab / Ipilimumab / Avelumab (3 cases, monotherapy) Melanoma / Merkel cell carcinoma ± Unknown Steroids Death / Improvement Shah et al., 2017 Pembrolizumab Bladder carcinoma + Unknown Steroids and etoposide Unknown Satzger et al., 2018 Ipilimumab and nivolumab Melanoma Not done No Steroids and mycophenolate mofetil Improvement Sadaat and Jang, 2018 Pembrolizumab Melanoma Not done No Steroids Improvement Hantel et al., 2018 Ipilimumab and nivolumab Melanoma + No Steroids Improvement Sasaki K et al., 2018 Pembrolizumab and BRAF inhibitors Melanoma Not done No Steroids Improvement Okawa et al., 2019 Pembrolizumab NSCLC + No Steroids Improvement Honjo et al., 2019 Nivolumab NSCLC Not done No Steroids and mycophenolate mofetil Improvement Laderian et al., 2019 Pembrolizumab Thymic cancer + Yes Steroids, Ig, anakinra Death Lorenz G et al., 2019 Pembrolizumab Prostate cancer + No Steroids+ plasmapheresis + etoposide + tacrolimus Improvement Al-Samkari H et al., 2019 Pembrolizumab Breast cancer Not done No Steroids Improvement Thummalapalli et al., 2020 Nivolumab and antiIDO Glioblastoma + Yes Steroids Death Continúa en la página siguiente